4//SEC Filing
HAQUE PROMOD 4
Accession 0001209191-21-028401
CIK 0001445499other
Filed
Apr 25, 8:00 PM ET
Accepted
Apr 26, 7:02 PM ET
Size
10.0 KB
Accession
0001209191-21-028401
Insider Transaction Report
Form 4
Norwest Venture Partners XIV, LP
10% Owner
Transactions
- Other
5% Convertible Note due 2021
2021-04-22Exp: 2021-12-31→ Common Stock (98,927 underlying)
Crowe Jeffrey
10% Owner
Transactions
- Other
5% Convertible Note due 2021
2021-04-22Exp: 2021-12-31→ Common Stock (98,927 underlying)
Kossow Jon Erik
10% Owner
Transactions
- Other
5% Convertible Note due 2021
2021-04-22Exp: 2021-12-31→ Common Stock (98,927 underlying)
HAQUE PROMOD
10% Owner
Transactions
- Other
5% Convertible Note due 2021
2021-04-22Exp: 2021-12-31→ Common Stock (98,927 underlying)
Footnotes (1)
- [F1]The convertible promissory note was issued by the issuer in March 2021 and the outstanding principal and accrued interest will automatically convert into the number of shares of the issuer's Common Stock set forth above upon the closing of the issuer's initial public offering (the "IPO") at $13.50 per share (90% of the IPO price). The conversion price became fixed upon pricing of the issuer's IPO on April 22, 2021.
Documents
Issuer
IMPEL NEUROPHARMA INC
CIK 0001445499
Entity typeother
IncorporatedCA
Related Parties
1- filerCIK 0001089744
Filing Metadata
- Form type
- 4
- Filed
- Apr 25, 8:00 PM ET
- Accepted
- Apr 26, 7:02 PM ET
- Size
- 10.0 KB